Notes

The fund is called Catalyst Research and it is for research purposes only. The fund size is 0 and the current time is 2026-09-17T13:31:02.879069+00:00. There are several news updates from various companies, including Telix Pharma on Thursday, September 17, 2026, Mission Produce on Tuesday, September 8, 2026, ABM on Tuesday, September 8, 2026, and Roivant on Tuesday, September 8, 2026. Additionally, there are financial reports from UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 14, 2026. Evolution Petroleum also reported its fiscal fourth quarter and full year results on Tuesday, September 15, 2026. There are also updates from IPHA on September 17, 2026, and hashes from KGF, ASKUL, IPHAnews, and SOBI. The research notes that IPHA has a conditional receipt for Q1-2028 and that certain monitors should be preserved. The sources and dates are listed in the job script and journal. There are no orders.

The fund, called Catalyst, is researching the stocks IONS, MIRM, GIS, and EAT, as well as CAG, with a size of 0. The research was done on September 17, 2026, at 11:31:01 UTC. The fund manager reviewed the following SEC filings: IONS on September 4, 2026, MIRM on September 8, 2026, GIS on July 1, 2026, and EAT on August 12, 2026. A discovery was made on September 9, 2026, that Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85. GIS had a conference on September 8, 2026, at 19:00 UTC, which has already passed. The fund manager will review the earnings of GIS on September 23, 2026, at 13:00 UTC. The baseline for GIS is an EPS of $3.00-3.20 for FY27, with organic growth of -1.5% to +0.5% and savings of $750 million. The fund manager will review EAT's investor day on September 17, 2026, at 16:30 UTC and its earnings call on October 28, 2026, at 16:30 UTC. The fund manager will verify the full pipelines and early news for the stocks.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 17, 2026, at 11:31:02 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. It also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the fund looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The fund also checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The fund will review new morning results on September 9 at 12:30, LOVE on September 10 at 12:30, and SFIX on September 24 at 12:30. The GRAL meeting on September 23 is not for approval. The fund has a strong cash position, which will be recorded and validated, while weak or early positions will be cashed out and reverified. No automatic orders were placed.

A fund called Catalyst Research was reviewed on 2026-09-17T09:46:09.774047+00:00. The review included compact receipts and information from the PRE91108 archive. The review consisted of 11 panels, which included information about various companies, including HITI and BFRI, and their SEC filings on 2026-09-14. There were also previews of news articles, including one about Dave & Buster's second quarter 2026 report on September 14, 2026. Other panels included information about TSM, DATA.L, CAN, PLAY, and EGTX, as well as conferences and reviews. One panel mentioned a photodynamic therapy system and a suspension being lifted by the ITC on September 1. The previews were based on raw data and it is recommended to read the originals before taking any action.

The Catalyst research fund has a size of 0 as of September 17, 2026, at 09:16:01 UTC. The fund manager reviewed the following news and reports: Telix Pharma on September 17, 2026, at https://telixpharma.com/news-views/lets-go-lets-get-them/, Mission Produce on September 8, 2026, at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial, ABM on September 8, 2026, at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results, and Roivant on September 8, 2026, at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. The manager also reviewed financial reports from UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, WLTH on September 14, 2026, and EPM on September 15, 2026. Additionally, the manager checked the following filings: EPM's fiscal fourth-quarter report, IPHA's 6-K filing on September 10, 2026, and verified the availability of information from KGF, ASKUL, IPHAnews, and SOBI. The manager decided to preserve monitors 165, 168, 167, 137, and 22, and noted that there are no orders. The manager also noted that IPHA has a conditional receipt for Q1 2028 and that research is limited to reading originals and validating information, with a focus on strong and new information, while weak or absent information requires cash and reverification.

The Catalyst fund is for research only on IONS, MIRM, GIS, and EAT, with no current size. As of September 17, 2026, at 07:16:05 UTC, the fund has the following notes: IONS filed with the SEC on September 4, 2026. MIRM filed with the SEC on September 8, 2026. GIS filed with the SEC on July 1, 2026. EAT filed with the SEC on August 12, 2026. On September 9, 2026, Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85. GIS had a conference on September 8, 2026, at 19:00 UTC. The fund will review earnings for GIS on September 23, 2026, at 13:00 UTC. For GIS, stronger organic cash flow and guidance will be recorded and validated, while weaker or absent results will require cash reverification. The baseline for GIS is an EPS of $3.00-3.20 for FY27, with organic growth of -1.5% to +0.5% and savings of $750 million. EAT will have an investor day on September 17, 2026, and an earnings call on October 28, 2026. The fund will review EAT's results on September 17, 2026, at 16:30 UTC and on October 28, 2026, at 16:30 UTC. The fund has no automatic trades and will verify full pipelines and early news for all four companies.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 17, 2026, at 07:16:05 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at news releases from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The manager also checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The manager noted that SEC filings may lag behind news and that reviews will be done at the following times: September 9 at 12:30 for new morning results, September 10 at 12:30 for LOVE, and September 24 at 12:30 for SFIX after the September 23 AMC. The manager also noted that the GRAL panel on September 23 is not for approval. The manager will use a strong cash position to record and validate, and a weak or early position to cash and reverify. No automatic orders were placed.

The Catalyst research fund has a size of 0 as of September 17, 2026, at 05:15:57 UTC. Recent news includes: TLX on September 13, 2026, with FDA approval for a brain cancer imaging drug, AVO on September 8, 2026, with fiscal third-quarter financial results, ABM on September 8, 2026, with fiscal third-quarter results, and ROIV on September 8, 2026, with positive results from a study. Financial reports were filed by UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 14, 2026. EPM reported fiscal fourth-quarter and full-year results on September 15, 2026. IPHA filed a 6-K report on September 10, 2026. HTTP requests were successful for KGF, ASKUL, IPHAnews, and SOBI with respective hashes. The research is for informational purposes only, with a note to read originals and validate strong or new information, and to cash and reverify weak or absent information. IPHA has a condition related to Sobi receipt and Q1-2028. Certain monitors are preserved, and sources and dates are recorded in the job script and journal. No orders were placed.

The Catalyst fund is currently in research mode only, with a size of 0, as of September 17, 2026, at 03:01:16 UTC. The fund is monitoring the following stocks: IONS, MIRM, GIS, and EAT, as well as CAG. The fund manager has reviewed SEC filings for IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on August 12. A discovery was made on September 9 that Barclays maintains an overweight rating on Ionis Pharmaceuticals, but lowers its price target to $85. The GIS conference was held on September 8 at 19:00 UTC, and the STATIC earnings report is scheduled for September 23 at 13:00 UTC. The fund manager will review the GIS earnings report and verify the results. The baseline for GIS is an EPS of $3.00-3.20 for FY27, with organic growth of -1.5% to +0.5% and savings of $750 million. The fund manager will also review the EAT investor day on September 17 and the earnings call on October 28. The fund manager has chosen to review the EAT reports at 16:30 UTC on the respective days. The fund is in research mode only, with no automatic trades, and the manager will verify the full pipelines and early news for the stocks.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 17, 2026, at 03:01:16 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at news releases from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The manager also checked the FDA website for information on GRAL, which had a panel meeting scheduled for September 23, 2026, but this was not an approval meeting. The manager will review the SEC filings again on the following dates: September 9 at 12:30 for new morning results, September 10 at 12:30 for LOVE, and September 24 at 12:30 for SFIX after the September 23 AMC. The manager will also review GRAL on September 23. The manager has a strong cash position and will validate and record it, but any weak or early signals will require cash reverification. There are no automatic orders in place.

A fund manager reviewed notes for the Catalyst research fund, which has a size of 0 and compact receipts. The origins of the notes are in the PRE91108 archive, and the review was done on 2026-09-17T01:46:04.692863+00:00. The review included 11 panels with various previews, including SEC filings for HITI and BFRI on 2026-09-14, a report from Dave & Buster's on September 14, 2026, and information about TSM, DATA.L, CAN, and EGTX. The previews also mentioned conferences and an ITC lifted suspension for BFRI on September 1, 2026. The fund manager has completed the review of the panels, which included raw sha and previews, and advises reading the originals before taking action.

The Catalyst research fund has a size of 0 as of September 17, 2026, at 01:01:11 UTC. Recent news includes TLX on September 13, 2026, where the FDA approved Telix's brain cancer imaging drug Pixclara, found at https://telixpharma.com/news-views/fda-approves-telixs-brain-cancer-imaging-drug-pixclara/. Also, AVO and ABM reported their fiscal 2026 third-quarter financial results on September 8, 2026, at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial and https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results, respectively. Additionally, ROIV announced positive results from the Phocus study of mosliciguat on September 8, 2026, at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. The fund also reviewed financial reports from UNFI, DRI, PPIH, MRK, and WLTH, with filing dates of September 14, July 24, September 9, August 7, and September 14, respectively. Furthermore, EPM reported its fiscal fourth-quarter and full-year results on September 15, 2026, at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-reports-fiscal-fourth-quarter-and-full-0. The fund checked the status of IPHA, KGF, ASKUL, IPHAnews, and SOBI, with HTTP200 hash values of 3313522fd352460d, e6f0d85c03a37ce6, 791fcefdafbc5a6c, and 7569409d160b2a08, respectively. The fund will preserve monitors 165, 168, 167, 137, and 22, and no orders were placed. A 10-K report is a comprehensive annual report required by the Securities and Exchange Commission, while a 10-Q report is a quarterly report, and a 6-K report is a periodic report filed by foreign private issuers. HTTP200 is a status code indicating a successful request.

The Catalyst fund is currently researching the stocks IONS, MIRM, GIS, and EAT, as well as CAG, with a size of 0. The fund's status was updated on September 16, 2026, at 23:01:14 UTC. The fund manager has been reviewing SEC filings for these stocks, including IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on August 12. A discovery was made on September 9 that Barclays maintains an overweight rating on Ionis Pharmaceuticals, but lowers its price target to $85. The GIS company had a conference on September 8, and its earnings will be released on September 23. The fund manager will review the earnings and verify the cash flow and guidance. If the organic cash flow is strong, it will be recorded and validated, but if it is weak or absent, the cash flow will be reverified. The baseline for GIS is an EPS of $3.00-3.20 and organic growth of -1.5% to +0.5%. The EAT company will have an investor day on September 17 and an earnings call on October 28. The fund manager will review these events and verify the first news release. The fund is currently in research mode only and has not placed any orders.

The job includes eight primary panels, including pre-open, and preserves80 (exit 0). The job involves analyzing the data from various sources, including CHWY SEC 2026-09-09 10-Q, ASO SEC 2026-09-10 10-Q, LOVE SEC 2026-09-10 10-Q, SFIX SEC 2026-07-28 8-K, SAIL RSS Wed, 09 Sep 26 07:00:50 -0400, KFY RSS Wed, 09 Sep 26 06:45:00 -0400, LOVE RSS Tue, 15 Sep 26 09:07:00 -0400, GRAL FDA {

The fund is called Catalyst Research and it is for research purposes only. The fund size is 0 and the time is 2026-09-16T21:01:04.423539+00:00. There are several news updates: TLX on Sunday, September 13, 2026, announced that the FDA approved Telix's brain cancer imaging drug Pixclara, which can be found at https://telixpharma.com/news-views/fda-approves-telixs-brain-cancer-imaging-drug-pixclara/. AVO on Tuesday, September 8, 2026, announced its fiscal 2026 third-quarter financial results, which can be found at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial. ABM on Tuesday, September 8, 2026, reported its fiscal third-quarter 2026 results, which can be found at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results. ROIV on Tuesday, September 8, 2026, announced positive results from the Phocus study of mosliciguat, which can be found at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. There are also several financial reports: UNFI's 10-K report for 2026, which can be found at 0001020859-26-000025/unfi-20260801.htm, DRI's 10-K report for 2026, which can be found at 0000940944-26-000025/dri-20260531.htm, PPIH's 10-Q report for 2026, which can be found at 0001437749-26-029988/ppih20260731_10q.htm, MRK's 10-Q report for 2026, which can be found at 0000310158-26-000212/mrk-20260630.htm, WLTH's 10-Q report for 2026, which can be found at 0001628280-26-061848/wlth-20260731.htm, and EPM's fiscal fourth-quarter and full-year report for 2026, which can be found at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-reports-fiscal-fourth-quarter-and-full-0. Additionally, there are several HTTP requests: KGF with a hash of 3313522fd352460d, ASKUL with a hash of e6f0d85c03a37ce6, IPHAnews with a hash of 791fcefdafbc5a6c, and SOBI with a hash of 7569409d160b2a08. The decision is to research only, with strong or new information requiring reading of originals and validation, and weak or absent information requiring cash and reverification. IPHA is scheduled for September 17, and Sobi receipt is conditional on Q1 2028. The monitors 165, 168, 167, 137, and 22 are to be preserved. There are no orders, and sources and dates can be found in the job script and journal.

The Catalyst fund is currently researching IONS, MIRM, GIS, and EAT, with no active orders. As of September 16, 2026, at 19:01:00 UTC, the fund size is 0. The fund has reviewed SEC filings from IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on August 12. On September 9, Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85. GIS had a conference on September 8, which has already passed. The fund will review GIS's earnings on September 23. The baseline for GIS's fiscal year 2027 is an EPS of $3.00-3.20, with organic growth of -1.5% to +0.5% and savings of $750 million. The fund has chosen to review EAT's investor day on September 17 and its earnings call on October 28. The fund will verify full pipelines and early news for IONS, MIRM, GIS, and EAT.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 16, 2026, at 19:00:58 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at news from SAIL, KFY, and LOVE, which were released on September 9, 2026, and September 15, 2026. The manager also checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The manager notes that SEC filings may lag behind news and will review results on September 9, 2026, at 12:30, and on September 10, 2026, at 12:30 for LOVE, and on September 24, 2026, at 12:30 for SFIX. The manager also notes that the GRAL panel on September 23, 2026, is not an approval. The manager will use a strong cash position to record and validate results, and a weak or early position to cash and reverify. No automatic orders were placed.

A fund manager's notes were found, which include information about a catalyst research fund with a size of 0. The notes mention compact receipts and origins in the PRE91108 archive, with a timestamp of 2026-09-16T17:46:00.624012+00:00. The notes also include a list of panels with previews of various news and updates, including SEC filings for HITI and BFRI on 2026-09-14, a report from Dave & Buster's on September 14, 2026, and updates on TSM, CAN, and EGTX. Additionally, the notes mention a lifted suspension by the ITC on September 1, 2026, and provide links to relevant websites. The notes are a collection of raw data and previews, and the originals should be read before taking any action.

The fund is called Catalyst Research and it has a size of 0 as of September 16, 2026, at 16:46:00 UTC. There are several news updates: Telix Pharma announced on September 13, 2026, that the FDA approved its brain cancer imaging drug Pixclara. Mission Produce announced its fiscal 2026 third quarter financial results on September 8, 2026. ABM reported its fiscal third quarter 2026 results on September 8, 2026. Roivant announced positive results from the Phocus study of mosliciguat on September 8, 2026. There are also several financial filings: UNFI filed its 10-K on September 14, 2026, DRI filed its 10-K on July 24, 2026, PPIH filed its 10-Q on September 9, 2026, MRK filed its 10-Q on August 7, 2026, and WLTH filed its 10-Q on September 14, 2026. Evolution Petroleum reported its fiscal fourth quarter and full year results on September 15, 2026. IPHA filed its 6-K on September 10, 2026. The HTTP requests for KGF, ASKUL, IPHAnews, and SOBI were successful with hashes 3313522fd352460d, e6f0d85c03a37ce6, 63c1ed7a93468887, and d719eca30b8a5a99, respectively. The research is ongoing, with a focus on reading originals and validating information. The fund will preserve its monitors and has no orders. A note is set for IPHA on September 17 and for Sobi receipt and Q1 2028 conditional.

The Catalyst fund is currently researching the stocks IONS, MIRM, GIS, and EAT, as well as CAG, with a size of 0. The fund's status was updated on September 16, 2026, at 14:46:07 UTC. The fund manager has been reviewing SEC filings for these stocks, including IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on August 12. A news scan found the headline that Barclays maintains an overweight rating on Ionis Pharmaceuticals and lowers its price target to $85 on September 9. The GIS company had a conference on September 8, and its earnings will be released on September 23. The fund manager will review the earnings and verify the company's organic cash and guidance. The baseline for GIS's FY27 EPS is 3.00-3.20, with organic growth of -1.5 to +0.5% and savings of $750 million. The fund manager will also review EAT's investor day on September 17 and its earnings call on October 28. The fund manager will verify the full pipelines and early news for these stocks and has chosen specific review times, but will not make any automatic trades. The fund's status was updated again on September 16, 2026, at 14:46:09 UTC, and it remains in research-only mode with no orders.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 16, 2026, at 14:46:06 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at news releases from SAIL, KFY, and LOVE. A news scan found the headline from SAIL about fiscal second-quarter 2027 results, from KFY about first-quarter fiscal 2027 results, and from LOVE about expanding seating offerings. The manager also checked FDA information about GRAL, which has a meeting on September 23, 2026, but this is not an approval. The manager will review results on September 9 at 12:30 UTC, LOVE results on September 10 at 12:30, and SFIX results on September 24 at 12:30, after the September 23 AMC. The manager will preserve cash at a record level if it is strong, but will reverify if it is weak, early, or absent. No automatic orders were placed.

The Catalyst research fund has a size of 0 as of September 16, 2026, at 12:31:11 UTC. Recent news includes TLX on September 13, 2026, where the FDA approved Telix's brain cancer imaging drug Pixclara, which can be found at https://telixpharma.com/news-views/fda-approves-telixs-brain-cancer-imaging-drug-pixclara/. Other news includes AVO on September 8, 2026, with Mission Produce announcing fiscal 2026 third-quarter financial results at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial, ABM on September 8, 2026, reporting fiscal third-quarter 2026 results at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results, and ROIV on September 8, 2026, announcing positive results from the Phocus study of mosliciguat at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. The fund also reviewed financial reports, including UNFI's 10-K report on September 14, 2026, at 0001020859-26-000025/unfi-20260801.htm, DRI's 10-K report on July 24, 2026, at 0000940944-26-000025/dri-20260531.htm, PPIH's 10-Q report on September 9, 2026, at 0001437749-26-029988/ppih20260731_10q.htm, MRK's 10-Q report on August 7, 2026, at 0000310158-26-000212/mrk-20260630.htm, and WLTH's 10-Q report on September 14, 2026, at 0001628280-26-061848/wlth-20260731.htm. Additionally, EPM reported fiscal fourth-quarter and full-year results on September 15, 2026, at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-reports-fiscal-fourth-quarter-and-full-0, and IPHA filed a 6-K report on September 10, 2026, at 0001628280-26-061214/a260910_6k.htm. The fund verified the integrity of data from KGF, ASKUL, IPHAnews, and SOBI, with HTTP200 hash values of 3313522fd352460d, e6f0d85c03a37ce6, 63c1ed7a93468887, and d719eca30b8a5a99, respectively. The fund will research IPHA on September 17, 2026, and has a conditional receipt for Sobi in Q1 2028. The fund preserves monitors 165, 168, 167, 137, and 22, with sources and dates found in the job script and journal. There are no orders, and the fund is for research purposes only, with a policy to read originals and validate strong or new information, and to cash and reverify weak, absent, or error information.

The Catalyst fund is currently in research mode only, with a size of 0, as of September 16, 2026, at 10:46:03 UTC. The fund is tracking the following stocks: IONS, MIRM, GIS, and EAT, with additional consideration for CAG. The fund manager has preserved 126 positions with an exit value of 0. The manager has reviewed SEC filings for IONS on September 4, 2026, MIRM on September 8, 2026, GIS on July 1, 2026, and EAT on August 12, 2026. A discovery update on September 9, 2026, noted that Barclays maintained an overweight rating on Ionis Pharmaceuticals, lowering its price target to $85. The manager also noted upcoming events, including a GIS conference on September 8, 2026, and earnings releases for GIS on September 23, 2026, and EAT on October 28, 2026. The manager has set specific criteria for evaluating these stocks, including organic cash growth and guidance, and has established frozen paper windows and stress tests. The manager has chosen specific review dates and times for these events, but has not set automatic trade orders. The fund manager will verify full pipelines and early news for these stocks.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 16, 2026, at 10:46:02 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. It also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the fund looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The fund also checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The fund will review new morning results on September 9 at 12:30, LOVE results on September 10 at 12:30, and SFIX results on September 24 at 12:30. The GRAL panel meeting on September 23 is not for approval. The fund has a strong cash position and will validate records, but weak or early results will require reverification. No automatic orders were placed.

A fund manager reviewed notes for the Catalyst research fund, which has a size of 0 and compact receipts, originating from the PRE91108 archive, on 2026-09-16T09:46:02.653753+00:00. The manager reviewed 11 panels of information, including SEC filings for HITI and BFRI on 2026-09-14, a report from Dave & Buster's on September 14, 2026, and information about TSM, DATA.L, CAN, and EGTX. The manager also noted that BFRI had an ITC lifted on September 1, 2026, and that there were upcoming conferences and calls for EGTX on September 11, 15, and 25. The manager reviewed these panels to make informed decisions about the fund.